Seqens Seqens

X
[{"orgOrder":0,"company":"Nectero Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nectero Medical Announces Initiation of Phase II\/III Clinical Trial of the Nectero EAST\u00ae System for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Nectero Medical","sponsor":"Norwest Venture Partners","pharmaFlowCategory":"D","amount":"$96.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nectero Medical Announces Completion of $96M Series D Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Nectero Medical

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The net Proceeds will be utilized to accelerate the clinical advancement of the Nectero EAST (pentagalloyl glucose) for the treatment abdominal aortic aneurysms.

            Lead Product(s): Pentagalloyl Glucose

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nectero EAST

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Norwest Venture Partners

            Deal Size: $96.0 million Upfront Cash: Undisclosed

            Deal Type: Series D Financing April 11, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Nectero EAST System is comprised of a dual-balloon delivery catheter and stabilizer mixture containing pentagalloyl glucose (PGG). It delivers PGG locally into the aneurysmal wall. It is under phase 2/3 for treatment of small- to medium-sized Abdominal Aortic Aneurysms.

            Lead Product(s): Pentagalloyl Glucose

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nectero EAST

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 18, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY